On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets ...

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

CHICAGO -- An investigational dual-action inhibitor for geographic atrophy (GA) significantly slowed disease progression and ...

KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseasesKT-621 is expected ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class ... of its Investigational New Drug (IND) application ...

Antag Therapeutics, a leading biopharmaceutical company focused on targeting the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor to pioneer novel treatments for obesity, today announced ...

today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a ...

LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal investigational ... to development of new drugs in the treatment ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA ...

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...